Fluoxymesterone therapy in anemia of patients on maintenance hemodialysis: comparison between patients with kidneys and anephric patients.
Nineteen patients with their kidneys and 11 anephric patients who were stable on maintenance hemodialysis received 20 mg a day of Fluoxymesterone. At the end of four months, there was a significant increase (p less than 0.005) in the mean hematocrit with a parallel increase in the hemoglobin level in both groups of patients. Concomitantly, we observed an increment of the red cell mass that was significant at the level of p less than 0.05. Blood transfusion requirements decreased significantly (p less than 0.1), independent of the presence or absence of kidneys. No changes in body weight, serum albumin, and serum cholesterol levels were observed. Secondary effects were hirsutism and hoarsening of the voice.
D000328:Adult; D000368:Aged; D000743:Anemia, Hemolytic / Q000188:drug therapy*; D001803:Blood Transfusion; D004911:Erythrocyte Volume / Q000187:drug effects; D004920:Erythropoiesis / Q000187:drug effects; D005260:Female; D005474:Fluoxymesterone / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D006435:Renal Dialysis
D005474:Fluoxymesterone